152 related articles for article (PubMed ID: 35932965)
1. Co-amorphous systems using epigallocatechin-3-gallate as a co-former: Stability, in vitro dissolution, in vivo bioavailability and underlying molecular mechanisms.
Chen J; Li H; Li X; Yuan D; Cheng H; Ke Y; Cheng J; Wang Z; Chen J; Li J
Eur J Pharm Biopharm; 2022 Sep; 178():82-93. PubMed ID: 35932965
[TBL] [Abstract][Full Text] [Related]
2. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia.
Martínez-Jiménez C; Cruz-Angeles J; Videa M; Martínez LM
Molecules; 2018 Aug; 23(9):. PubMed ID: 30154310
[TBL] [Abstract][Full Text] [Related]
3. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
4. Co-solvent evaporation method for enhancement of solubility and dissolution rate of poorly aqueous soluble drug simvastatin: in vitro-in vivo evaluation.
Pandya P; Gattani S; Jain P; Khirwal L; Surana S
AAPS PharmSciTech; 2008; 9(4):1247-52. PubMed ID: 19115110
[TBL] [Abstract][Full Text] [Related]
5. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
6. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation.
Lodagekar A; Chavan RB; Mannava MKC; Yadav B; Chella N; Nangia AK; Shastri NR
Eur J Pharm Sci; 2019 Nov; 139():105048. PubMed ID: 31446077
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin-Nicotinamide Co-Crystals: Formation, Pharmaceutical Characterization and in vivo Profile.
Khan FM; Ahmad M; Idrees HA
Drug Des Devel Ther; 2020; 14():4303-4313. PubMed ID: 33116417
[TBL] [Abstract][Full Text] [Related]
9. Extruded Soluplus/SIM as an oral delivery system: characterization, interactions, in vitro and in vivo evaluations.
Zhang Y; Liu Y; Luo Y; Yao Q; Zhong Y; Tian B; Tang X
Drug Deliv; 2016 Jul; 23(6):1902-11. PubMed ID: 25268150
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.
Craye G; Löbmann K; Grohganz H; Rades T; Laitinen R
Molecules; 2015 Dec; 20(12):21532-48. PubMed ID: 26633346
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
12. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.
Hu D; Chen X; Li D; Zhang H; Duan Y; Huang Y
Int J Pharm; 2023 Mar; 635():122707. PubMed ID: 36764418
[TBL] [Abstract][Full Text] [Related]
13. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
15. Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study.
Guo W; Dong X; Li Y; Li C; Tian Y; Gao H; Li T; Zhu H; Wang J; Yang C
Eur J Pharm Biopharm; 2023 Mar; 184():139-149. PubMed ID: 36709922
[TBL] [Abstract][Full Text] [Related]
16. A computational-based approach to fabricate Ceritinib co-amorphous system using a novel co-former Rutin for bioavailability enhancement.
Yarlagadda DL; Anand VSK; Nair AR; Dengale SJ; Pandiyan S; Mehta CH; Manandhar S; Nayak UY; Bhat K
Eur J Pharm Biopharm; 2023 Sep; 190():220-230. PubMed ID: 37524214
[TBL] [Abstract][Full Text] [Related]
17. Platensimycin-berberine chloride co-amorphous drug system: Sustained release and prolonged half-life.
Wang Z; Chen X; Li D; Bai E; Zhang H; Duan Y; Huang Y
Eur J Pharm Biopharm; 2022 Oct; 179():126-136. PubMed ID: 36087879
[TBL] [Abstract][Full Text] [Related]
18. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
19. Non-salt based co-amorphous formulation produced by freeze-drying.
Suleiman Alsalhi M; Royall PG; Al-Obaidi H; Alsalhi A; Cilibrizzi A; Chan KLA
Int J Pharm; 2023 Oct; 645():123404. PubMed ID: 37714312
[TBL] [Abstract][Full Text] [Related]
20. Crystal engineering of green tea epigallocatechin-3-gallate (EGCg) cocrystals and pharmacokinetic modulation in rats.
Smith AJ; Kavuru P; Arora KK; Kesani S; Tan J; Zaworotko MJ; Shytle RD
Mol Pharm; 2013 Aug; 10(8):2948-61. PubMed ID: 23730870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
